[Heparanase and vascular endothelial growth factor expression in non-small-cell lung cancer].
OBJECTIVE
To study the clinicopathological significance of heparanase and VEGF expression in NSCLC.


METHODS
Eighty-five lung samples were studied. Each sample was divided into two parts, one used for heparanase mRNA detection by reverse transcription PCR and the other for VEGF detection by immunohistochemistry.


RESULTS
(1) The expressions of heparanase mRNA and VEGF were higher in NSCLC than in benign pulmonary diseases (P < 0.05). (2) The expression of heparanase mRNA was higher in cases with lymph-node invasion, metastasis, stage III and IV diseases, low-differentiation, and adenocarcinoma, as compared to cases without lymph-node invasion and metastasis, with stage I and II diseases, higher and moderate differentiation, and squamous cell cancer (P < 0.05). Its expression was higher in tumors larger than 5 cm in size (P < 0.05). (3) The expression of VEGF was higher in cases with lymph-node invasion, metastasis, and stage III and IV disease, as compared to cases without lymph-node invasion and metastasis, and with stage I and II diseases (P < 0.05). (4) There was no significant correlation between heparanase and VEGF expression (P > 0.05).


CONCLUSIONS
Heparanase and VEGF are associated with NSCLC invasion and metastasis, and may be used to evaluate NSCLC metastasis status. Heparanase and VEGF promote NSCLC invasion and metastasis by independent mechanisms. Detection of these two markers may improve the sensitivity and specificity of the measurement of NSCLC metastatic potential.
Gao
Xia
X
Department of Thoracic Surgery, Henan Chest Hospital, Zhengzhou 450003, China.
Liang
Qing-zheng
QZ
Wu
Xue-qiang
XQ
Li
Sui-ying
SY
Bai
Han-lin
HL
Zhang
Shu-lin
SL
Qi
Min-xian
MX
Yuan
Wu-ying
WY
Wang
Jian-wei
JW
Wang
Guo-bin
GB
D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000096:biosynthesis; D002289:Carcinoma, Non-Small-Cell Lung / Q000378:metabolism* / Q000556:secondary; D016228:Endothelial Growth Factors / Q000096:biosynthesis*; D005260:Female; D005966:Glucuronidase / Q000096:biosynthesis* / Q000235:genetics; D006801:Humans; D066298:In Vitro Techniques; D008175:Lung Neoplasms / Q000378:metabolism* / Q000473:pathology; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D012333:RNA, Messenger / Q000096:biosynthesis; D020133:Reverse Transcriptase Polymerase Chain Reaction; D000099175:Heparanase
D014408:Biomarkers, Tumor; D016228:Endothelial Growth Factors; D005966:Glucuronidase; D012333:RNA, Messenger; D000099175:Heparanase